Shanghai Bio-heart Biological Technology (HKG:2185) subsidiary Zhejiang Bioheart Medical Equipment will receive a 155.6 million yuan capital injection from Jiaxing Guojian Baixin Equity Investment Partnership Enterprise in exchange for a 45.3208% stake in Zhejiang Bioheart.
Upon completion of the capital increase, Shanghai Bio-heart's stake in Zhejiang Bioheart will be reduced to 54.6792%, with Jiaxing Guojian Baixin Equity Investment Partnership Enterprise holding the remainder.
Price (HKD): $1.64, Change: $-0.050, Percent Change: -2.96%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.